Collapsing glomerulopathy

Mamdouh Albaqumi, Timothy J. Soos, Laura Barisoni-Thomas, Peter J. Nelson

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Collapsing glomerulopathy (CG) has become an important cause of ESRD. First delineated from other proteinuric glomerular lesions in the 1980s, CG is now recognized as a common, distinct pattern of proliferative parenchymal injury that portends a rapid loss of renal function and poor responses to empiric therapy. Notwithstanding, the rise in disorders that are associated with CG, the identification of the first susceptibility genes for CG, the remarkable increase in murine modeling of CG, and promising preclinical testing of new therapeutic strategies suggest that the outlook for CG as a poorly understood and therapeutically resistant renal disease is set to change in the future. This focused review highlights recent advances in research into the pathogenesis and treatment of CG.

Original languageEnglish
Pages (from-to)2854-2863
Number of pages10
JournalJournal of the American Society of Nephrology
Volume17
Issue number10
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

Kidney
Chronic Kidney Failure
Wounds and Injuries
Therapeutics
Research
Genes

ASJC Scopus subject areas

  • Nephrology

Cite this

Collapsing glomerulopathy. / Albaqumi, Mamdouh; Soos, Timothy J.; Barisoni-Thomas, Laura; Nelson, Peter J.

In: Journal of the American Society of Nephrology, Vol. 17, No. 10, 01.10.2006, p. 2854-2863.

Research output: Contribution to journalArticle

Albaqumi, Mamdouh ; Soos, Timothy J. ; Barisoni-Thomas, Laura ; Nelson, Peter J. / Collapsing glomerulopathy. In: Journal of the American Society of Nephrology. 2006 ; Vol. 17, No. 10. pp. 2854-2863.
@article{5a5c4e5a5b3a4b19852dddaea7303309,
title = "Collapsing glomerulopathy",
abstract = "Collapsing glomerulopathy (CG) has become an important cause of ESRD. First delineated from other proteinuric glomerular lesions in the 1980s, CG is now recognized as a common, distinct pattern of proliferative parenchymal injury that portends a rapid loss of renal function and poor responses to empiric therapy. Notwithstanding, the rise in disorders that are associated with CG, the identification of the first susceptibility genes for CG, the remarkable increase in murine modeling of CG, and promising preclinical testing of new therapeutic strategies suggest that the outlook for CG as a poorly understood and therapeutically resistant renal disease is set to change in the future. This focused review highlights recent advances in research into the pathogenesis and treatment of CG.",
author = "Mamdouh Albaqumi and Soos, {Timothy J.} and Laura Barisoni-Thomas and Nelson, {Peter J.}",
year = "2006",
month = "10",
day = "1",
doi = "10.1681/ASN.2006030225",
language = "English",
volume = "17",
pages = "2854--2863",
journal = "Journal of the American Society of Nephrology",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "10",

}

TY - JOUR

T1 - Collapsing glomerulopathy

AU - Albaqumi, Mamdouh

AU - Soos, Timothy J.

AU - Barisoni-Thomas, Laura

AU - Nelson, Peter J.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Collapsing glomerulopathy (CG) has become an important cause of ESRD. First delineated from other proteinuric glomerular lesions in the 1980s, CG is now recognized as a common, distinct pattern of proliferative parenchymal injury that portends a rapid loss of renal function and poor responses to empiric therapy. Notwithstanding, the rise in disorders that are associated with CG, the identification of the first susceptibility genes for CG, the remarkable increase in murine modeling of CG, and promising preclinical testing of new therapeutic strategies suggest that the outlook for CG as a poorly understood and therapeutically resistant renal disease is set to change in the future. This focused review highlights recent advances in research into the pathogenesis and treatment of CG.

AB - Collapsing glomerulopathy (CG) has become an important cause of ESRD. First delineated from other proteinuric glomerular lesions in the 1980s, CG is now recognized as a common, distinct pattern of proliferative parenchymal injury that portends a rapid loss of renal function and poor responses to empiric therapy. Notwithstanding, the rise in disorders that are associated with CG, the identification of the first susceptibility genes for CG, the remarkable increase in murine modeling of CG, and promising preclinical testing of new therapeutic strategies suggest that the outlook for CG as a poorly understood and therapeutically resistant renal disease is set to change in the future. This focused review highlights recent advances in research into the pathogenesis and treatment of CG.

UR - http://www.scopus.com/inward/record.url?scp=33749256664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749256664&partnerID=8YFLogxK

U2 - 10.1681/ASN.2006030225

DO - 10.1681/ASN.2006030225

M3 - Article

C2 - 16914539

AN - SCOPUS:33749256664

VL - 17

SP - 2854

EP - 2863

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

SN - 1046-6673

IS - 10

ER -